Exelixis will pay Invenra $15 million upfront on an expanded collaboration and licensing agreement that includes 20 new oncology targets.

This story is part one in a two-part series looking at the psychedelics drug development landscape. Part two, which examines the regulatory issues and clinical applications, is available here.

CytoDyn’s efforts to get leronlimab past the regulatory finish line in any indication has been a saga—including an incident in which the biotech sent the wrong data sets to the FDA. But now, the regulator seems to have pointed the biotech in the right direction for a filing for approval in HIV.

Eli Lilly is gunning for Regeneron and Sanofi’s blockbuster Dupixent. Having paid $1.1 billion to enter the IL-13 space last year, Lilly has now revealed the success of its challenger in two pivotal trials—but it’s yet to share the numbers that will show whether lebrikizumab is a true contender for the throne.

Recovering from a stroke is a long, arduous process, requiring months or even years of speech, physical and occupational therapy to regain even a semblance of a patient’s previous abilities. During those sessions, the brain is essentially healing itself, an imperfect process that can result in chronic health conditions for at least half of stroke survivors.

Soon, Apple announced recently, it will enable doctors to monitor health data from their patients’ phones and watches between visits, part of the push into health care that Tim Cook, Apple’s CEO, has declared will constitute the company’s greatest contribution to mankind.

Biopharma ATAI Life Sciences is unveiling yet another subsidiary to tackle mental health, this time with an agonist from a psychoactive plant in the mint family with hallucinogenic effects.

PureTech Health has pieced together a wholly owned pipeline in recent years, picking up a prospect from Teva while taking ownership of Ariya Therapeutics and Alivio Therapeutics. With the expansion ratcheting up PureTech’s need for clinical trial expertise, the biotech has lured Julie Krop, M.D., away from Freeline Therapeutics.

The curse of palovarotene continues. After struggling through a series of setbacks, Ipsen filed for FDA approval of the rare disease drug earlier this year, moving it a step closer to realizing some return on its $1 billion bet on the asset. Now, Ipsen has pulled the filing.

When it comes to iconic duos, the best are those that, together, equal more than the sum of their parts, like peanut butter and jelly, Calvin and Hobbes and, according to Mahana Therapeutics, the brain and the gut.